Pharmacokinetics of single-dose doripenem in adults with cystic fibrosis

Journal of Clinical Pharmacology

Volumn 52, Issue 11, 2012, Pages 1645-1653

  Cirillo, Iolanda ^a   Vaccaro, Nicole ^a   Redman, Rebecca ^a   Black, Philip L ^b   Kearns, Gregory L ^c  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b Cystic Fibrosis Center   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

cystic fibrosis; Doripenem; pharmacokinetics; prolonged infusion; safety

Indexed keywords

DORIPENEM; DORIPENEM M 1; DRUG METABOLITE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; MALE; NAUSEA; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CYSTIC FIBROSIS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; YOUNG ADULT;

EID: 84868005701     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011427564     Document Type: Article

References (16)

1. Cystic Fibrosis Foundation. About cystic fibrosis. http://www.cff.org/ AboutCF/
2. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003 ; 168: 918-951 (Pubitemid 37267172)
3. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc ; 2008 :
4. Traczewski MM, Brown SD. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob Agents Chemother. 2006 ; 50: 819-821 (Pubitemid 43191012)
5. Crandon JL, Bulik CC, Nicolau DP. In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2009 ; 53: 4352-4356
6. Mazzei T. The pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenem. J Chemother. 2010 ; 22: 219-225
7. Prandota J. Clinical pharmacology of antibiotics and other drugs in cystic fibrosis. Drugs. 1988 ; 35: 542-578
8. Cirillo I, Vaccaro N, Turner K, Solanki B, Natarajan J, Redman R. Pharmacokinetics, safety, and tolerability of doripenem after 0.5-, 1-, and 4-hour infusions in healthy volunteers. J Clin Pharmacol. 2009 ; 49: 798-806
9. Ritschel WA, Kearns GL Handbook of Basic Pharmacokinetics... Including Clinical Applications. 6 th ed.Washington, DC: American Pharmacists Association; 2004. Washington, DC: American Pharmacists Association ; 2004 :
10. Van Wart SA, Andes DR, Ambrose PG, Bhavnani SM. Pharmacokinetic- pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients. Diagn Microbiol Infect Dis. 2009 ; 63: 409-414
11. Morison S, Dodge JA, Cole TJ, et al. Height and weight in cystic fibrosis: a cross sectional study. UK Cystic Fibrosis Survey Management Committee. Arch Dis Child. 1997 ; 77: 497-500 (Pubitemid 28016367)
12. Patel L, Dixon M, David TJ. Growth and growth charts in cystic fibrosis. J R Soc Med. 2003 ; 96: 35-41 (Pubitemid 36842985)
13. Christensson BA, Ljungberg B, Eriksson L, Nilsson-Ehle I. Pharmacokinetics of meropenem in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 1998 ; 17: 873-876 (Pubitemid 29219157)
14. Doring G, Conway SP, Heijerman HG, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000 ; 16: 749-767
15. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect. 2005 ; 11: 974-984 (Pubitemid 41748931)
16. Kuti JL, Nightingale CH, Knauft RF, Nicolau DP. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. Clin Ther. 2004 ; 26: 493-501 (Pubitemid 38586450)